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The yeast suppressor of myosin 2 protein (Smy2)
interacts with mRNA-processing proteins through
recognition of proline-rich sequences (PRS). Here,
we describe the crystal structure of the GYF domain
of Smy2 in association with a PRS from the yeast
branch point binding protein (BBP/ScSF1). Complex
formation requires that the b-hairpin of the central
PPGL motif of the ligand is accommodated by an
extended hydrophobic cleft in the domain—a speci-
ficity feature that is maintained in the human protein
GIGYF2. SILAC/MS experiments in combination
with PRS site inhibition show that Smy2 associates
with the Ccr4-NOT deadenylase complex, whereas
GIGYF2 interacts not only with mRNA surveillance
factors, but also with vesicular transport proteins
and Atrophin-1. GIGYF2 is shown to associate
with COPII-vesicle proteins and localize to the ER
and Golgi in resting cells, whereas environmental
challenge drives GIGYF2 into stress granules. The
current study highlights the structural basis for PRS
recognition by Smy2-type GYF domains, and impli-
cates Smy2 and GIGYF2 in both mRNA processing
and the secretory pathway.
INTRODUCTION
The recognition of proline-rich sequences (PRS) by protein
adaptor domains has emerged as a universal mechanism for
shaping cellular signaling responses by means of semispecific
and relatively low affinity protein interactions. There are several
domains that recognize PRS, including SH3, WW, EVH1, UEV,
and GYF domains (Kay et al., 2000; Kofler and Freund, 2006;
Musacchio et al., 1994; Zarrinpar et al., 2003), and they all capi-
talize on the favorable interaction between proline rings from
the ligand and stacked aromatic amino acid side-chains on the
surface of these domains. The GYF family of PRS-recognizing944 Structure 18, 944–954, August 11, 2010 ª2010 Elsevier Ltd All riscaffolds are hallmarked by a conserved signature, GPF-X4-
[M/V/I]-X2-W-X3-GYF forming a bulge-helix-bulge structure,
and by a b1-b2-loop region that represents the distinguishing
feature of the two major subfamilies of GYF domains. The
subfamilies are named after the proteins in which they were first
identified—human CD2 binding protein 2 (CD2BP2) (Freund
et al., 1999; Nishizawa et al., 1998) and the suppressor of Myosin
2 (Smy2) protein in Saccharomyces cerevisiae (Lillie and Brown,
1992). CD2BP2-typeGYFdomains are characterized by a trypto-
phan at position 22 and a longer loop between b strands 1 and 2
(Figure 1). This subfamily selects primarily for the consensus
sequence PPGW but also recognizes a secondary class of
ligands with a PPG-X-(R/K) motif (Kofler et al., 2005a; Kofler
et al., 2005b). In the Smy2 subfamily, tryptophan 22 is replaced
by an aspartic acid residue, and the domain prefers ligands with
the consensus motif PPGf (where f = hydrophobic amino acid,
except for tryptophan). The structure of the CD2BP2 GYF
domain in complex with a PRS from the T cell adhesion molecule
CD2 led to a model of ligand specificity for this type of GYF
domain, whereas an understanding of the PRS recognition prin-
ciples for the larger Smy2 class remains largely speculative.
In eukaryotes, the GYF domain subfamilies might be
correlated with different functional roles. Proteins containing
CD2BP2-type GYF domains are located in the nucleus and are
involved in pre-mRNA splicing (Bialkowska and Kurlandzka,
2002; Kofler et al., 2004, 2005a; Laggerbauer et al., 2005;
Nielsen et al., 2007). In contrast, proteins containing Smy2-
type GYF domains seem to be involved in translational control
and are hence found in the cytoplasm and its compartments
(Giovannone et al., 2003; Huh et al., 2003).
Yeast Smy2 was first cloned as a multicopy suppressor of
Myo2, a type V myosin involved in vesicular transport (Lillie
and Brown, 1992). Mounting evidence now suggests that the
81.4 kDa yeast Smy2 protein is involved in both mRNA surveil-
lance (Georgiev et al., 2007; Kofler et al., 2005b) and also
membrane-associated processes (Higashio et al., 2008; Sezen
et al., 2009). More specifically, genetic screening has suggested
that Smy2 and its homolog Syh1 (also called Myr1) are associ-
ated with the secretory pathway (Georgiev et al., 2008; Higashio
et al., 2008), and Smy2 was shown to act as a multicopy
suppressor of a temperature sensitive Sec24 mutant (Higashioghts reserved
Figure 1. Sequence Alignment for Smy2-Type GYF Domains (Smy2 and GIGYF2) and CD2BP2-Type GYF Domains (Lin1 and CD2BP2)
The conserved elements defining the overall GYF domain fold are highlighted in gray. Features distinguishing the two subfamilies and determining their specificity
are highlighted in black. Sc and Hs indicate Saccharomyces cerevisiae and Homo sapiens, respectively. The sequence alignments show the minimal core of the
GYF domain. Residues and secondary structural elements C-terminal to this core are variable between GYF domains.
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Structure and Function of Smy2-Type GYF Domainset al., 2008). However, a direct interaction between Smy2 and
the Sec23/Sec24 complex could be observed only in the
Sec24 mutant background but not in wild-type cells. Most
intriguing is a recent study by Sezen et al. (2009) that assigns
a function to the Smy2-GYF domain because of its interaction
with the PRS motifs of the translational repressor Eap1. These
two proteins are part of a larger protein complex that regulates
the ER-localized translation initiation of the nuclear membrane
protein POM34, thereby allowing spindle pole body formation
to progress in the absence of membrane tethering.
Apparently unrelated to the results from genetic studies are
earlier yeast-two-hybrid results (Fromont-Racine et al., 2000)
and more recent experiments from our group suggesting that
Smy2 is involved in mRNA processing pathways (Kofler et al.,
2005b). Smy2 was shown to interact with PRS of the yeast
branch-point binding protein (BBP; also known as ScSF1 and
Msl5)—an essential component of the splicing commitment
complex 2 in yeast. In silico predictions based on the PPGf
recognition motif also identified components of the Ccr4-NOT
transcriptional regulation complex as putative interaction part-
ners of Smy2 (Georgiev et al., 2007; Kofler et al., 2005b). Ccr4-
NOT is a deadenylase complex responsible for the degradation
of mRNA polyA tails in cytoplasmic processing (P) bodies, and
it was shown that both full-length Smy2 and the isolated GYF
domain are able to localize to P bodies (Georgiev et al., 2007).
In humans, the 150 kDa GIGYF2 protein is one of only
two proteins containing a Smy2-type GYF domain. The other,
GIGYF1, shares 52% overall identity with GIGYF2, and 81%
identity in its GYF domain. Both these proteins were originally
identified as Grb10-interacting proteins in the context of insulin
signaling in mice (Giovannone et al., 2003), and recently a poten-
tial genetic linkage between GIGYF2 and Parkinson’s disease
has been debated controversially (Bras et al., 2009; Lautier
et al., 2008). However, at a molecular level, little is known about
GIGYF protein function.
The current study seeks to structurally describe the interaction
between Smy2-type GYF domains and their binding partners,
and to more clearly elucidate the function of Smy2-GYF
domain-containing proteins. Crystal structures of the GYF
domain from Smy2 both alone and in complex with a proline-
rich peptide reveal the presence of a deep hydrophobic pocket
within the domain that accommodates the PPGf recognition
motif of the ligand and distinguishes this subfamily from
CD2BP2-type GYF domains.Structure 18, 94Potential in vivo binding partners for GIGYF2 and Smy2 were
identified using the SILAC/MS pull-down method, which was
exploited to selectively detect proteins and protein complexes
bound via proline-rich sequences in the same manner identified
in the structural studies. A common set of spliceosomal proteins
are recognized by both Smy2 and GIGYF2, yet although Smy2
primarily interacts with components of the Ccr4-NOT complex,
GIGYF2 is associated with distinct mRNA surveillance factors,
Atrophin-1, and COPII vesicular proteins. Live cell microscopy
mapped GIGYF2 to ER and Golgi compartments under normal
cellular conditions; however, treatment of cells with arsenite
drives GIGYF2 into TIA-1–containing stress granules. The results
from the current study suggest a functional link between mRNA
surveillance and the secretory system in both yeast and humans.
RESULTS
The Structure of the GYF Domain of Smy2
The domain alone crystallized as a domain-swapped dimer,
whereas the ligand-bound form crystallized as both a monomer
and a domain-swapped dimer within the same crystal (for data
processing and refinement statistics, see Table 1). The domain
swap involves the C-terminal helices of two adjacent molecules
(residues 83–96). With the exception of a five-residue hinge
region distal to the ligand binding site, the structure of the
domain is fully preserved between the domain-swapped and
nonswapped forms. Superposition of the ligand-bound domain-
swapped structure (residues 11–77 and 830–960 from the neigh-
boring molecule) onto the ligand-bound monomer gives a back-
bone rmsd of 0.22 A˚. Except for the hinge region, it is thus valid to
consider the domain-swapped form of the peptide-free structure
to be fully representative of the true domain fold.
The Smy2-GYF domain retains all the structural hallmarks of
the core GYF domain (Freund et al., 1999; Freund et al., 2002;
Nielsen et al., 2007). Like CD2BP2-GYF, the core domain is
defined by a three-stranded antiparallel b sheet, with two
a helices packed against one face (Figure 2). The first of
these helices (a1) tilts away from the sheet, creating a cradle in
which a set of highly conserved hydrophobic residues form the
ligand binding site. Outside this core region that contains the
ligand-binding site, different GYF domains have a variable C-
terminal region. In the GYF domain of Smy2, this is an additional
C-terminal helix (a3), which packs between a1 and a2 primarily via
hydrophobic contacts with the b sheet. The loop between a2 and4–954, August 11, 2010 ª2010 Elsevier Ltd All rights reserved 945
Table 1. Crystallographic Data and Refinement Statistics for the
Unligated and Complexed Smy2-GYF-Ligand Complex
Unligated Complex
Inflection point Peak
Data processing
Wavelength (A˚) 0.91841 0.97875 0.97852
Space group P6522 P42212
Unit cell parameters
a, b, c (A˚) 68.4, 68.4,
111.3
101.4, 101.4, 150.7
Resolution (A˚) 50–1.80
(1.90–1.80)
50–2.60
(2.74–2.60)
50–2.50
(2.64–2.50)
Unique reflections 14,884 (2107) 25,254 (3609) 27,942 (4003)
Completeness (%) 99.8 (99.7) 99.9 (100) 100 (100)
Rmerge
a 0.075 (0.656) 0.102 (0.792) 0.123 (0.878)
Rp.i.m
b 0.017 (0.146) 0.030 (0.251) 0.032 (0.284)
I/<s(I)> 31.4 (5.2) 19.2 (2.8) 17.8 (2.1)
Redundancy 20.9 (20.2) 12.3 (10.7) 15.1 (10.5)
Refinement
Resolution (A˚) 25.2–1.80
(1.85–1.80)
— 50–2.50
(2.57–2.50)
Unique reflections 14,090 (1055) — 27,895 (2024)
Completeness (%) 99.6 (99.6) — 100 (100)
Total number atoms 745 — 3609
Total number waters 84 — 3
<Protein B-factor> (A˚2)c 26.4 — 62.2
rmsdbonds (A˚) 0.011 — 0.012
rmsdangles (
) 1.497 — 1.557
Ramachandran plotd
Favored (%) 98.8 — 97.7
Additionally allowed (%) 1.2 — 2.3
Rwork
e 0.208 (0.235) — 0.225 (0.332)
Rfree
f 0.224 (0.274) — 0.250 (0.341)
Note:values in parentheses are for the highest resolution shell.
a Rmerge =
P
hkl
P
j jIj(hkl)  <I(hkl)>j/
P
hkl
P
j Ij(hkl).
b Rp.i.m =
P
hkl [(1/N  1)]1/2
P
j jIj(hkl) –%I(hkl)>j/
P
hkl
P
j Ij(hkl).
c Calculated as sum of residual isotropic B factors and anisotropic TLS
displacement parameters.
d As calculated by MolProbity (Davis et al. 2007).
e Rwork =
P
hkl jFobs  Fcalcj/
P
hkl jFobsj.
f Calculated using 5% of the diffraction data that were excluded during
refinement.
Figure 2. Structure of the GYF Domain of Smy2
The domain is composed of a three-stranded b sheet, with three alpha helices
stacked against it.
Figure 3. A Proline-Rich Ligand Bound to the GYF Domain of Smy2
Conserved binding site residues from the domain are shown in blue sticks. The
ligand is shown in yellow sticks, and the critical PPGf residues correspond to
P6, P7, G8, and L9. Hydrogen bonds are shown as black dashes. Inset shows
hydrogen bonds maintaining the side-chain orientation of D22.
Structure
Structure and Function of Smy2-Type GYF Domainsa3 exists in two different conformations, giving rise to either
monomeric or domain-swapped Smy2-GYF. For the ligand-
bound form, the asymmetric unit contains one monomer and
two domain-swapped dimers, with each of the five protein
domains bound to one ligand molecule (see Figure S1 available
online). The ligand binding site is unvarying in all molecules in the
asymmetric unit, and further figures will focus on the domain-
ligand complex of the monomeric form of the domain.
Turn Recognition in Proline-Rich Peptides
by Smy2-Type GYF Domains
For crystallization studies, we selected an 11-residue fragment
of the pre-mRNA BBP, which is known to interact with Smy2946 Structure 18, 944–954, August 11, 2010 ª2010 Elsevier Ltd All ri(Kofler et al., 2005b) and contains the canonical PPGf recogni-
tion motif (SSIAPPPGLSG). GYF domain residues Y20, F31,
W39, Y44, F45, and L49 form the binding pocket (Figure 3).
Only the core motif APPPGL could be clearly visualized for all
ligands in the asymmetric unit, and all other ligand residues are
disordered. The consensus motif binds in a polyproline type II
(PPII) helical conformation. Hydrogen bonds are formed
between the ligand P5 and P7 backbone carbonyls and the
side-chains of residues W39 and Y20, respectively. Prolines P6
and P7 pack into a hydrophobic cavity created by the highly
conserved residues Y20, F31, W39, and F45, with P6 forming
a stacking interaction with W39. G8 induces a type II beta-turn
following the PPII helix. Any other residue at this position cannot
be tolerated, because Cb hydrogens would clash with residues
D22 and H28 from the GYF domain. The tight beta-turn orients
the L9 side-chain toward an extended hydrophobic patch of
the domain formed by Y20, F45, and L49.ghts reserved
Figure 4. Proteomic Analysis of Smy2-Type GYF Domain Interaction
Partners
The principle of the SILAC experiment is shown in the upper panel. The pull-
downs from either yeast (Smy2) or humanHeLa (GIGYF2) cell lysates were per-
formed with GST-GYF domains in the absence or presence of inhibitory
peptide. Peptide-inhibited and peptide-free samples were subsequently
mixed and analyzed by 1D-PAGE. 13C enrichment in the respective MS
spectra is indicative of proteins that are specifically bound by the PRS site
of the respective GYF domain. In the lower panels, schematic representations
of 13C-enriched proteins that belong to functionally important classes
are shown. Proteins containing the GYF consensus motif PPGf are depicted
as bold italic underlined. The color coding is graded according to mass
spectrometric 13C enrichment factors. Direct interactions among identified
proteins are indicated by overlapping circles and solid lines, whereas genetic
interactions are indicated by a punctured line; interactions derived from
Tap-tag pull-down experiments are shown as dashed lines (see http://www.
yeastgenome.org/).
Structure
Structure and Function of Smy2-Type GYF DomainsThe overall structure of the domain is essentially invariable
between the ligated and unligated forms, having an rmsd in Ca
positions of 0.55 A˚ for residues 15–73 when superimposing the
two forms. Most important, ligand binding appears to follow a
‘‘lock and key’’ mechanism, because side-chain residues at
the binding site share the same orientation in the two structures.
Binding Partners of Smy2-GYF Domains in Yeast
and Humans
Although the core structural features that govern PRS
recognition seem to be fully conserved for all Smy2-type GYF
domains, the interactome of the domain might well be distinct
for individual proteins, perhaps being dictated by subcellular
localization, the availability of species-specific binding partners,
or the nature of the variable C-terminal region of the domain. To
profile the Smy2-GYF domain interactome from yeast and
humans, pull-down experiments with the Smy2 and GIGYF2
GYF domains were performed using S. cerevisiae and HeLa cell
lysates, respectively. Specific interactions were distinguished
from unspecific binding events by performing SILAC/MS
experiments in combination with competition for PRS-binding
sites by proline-rich peptides (Figure 4). The inhibitory peptides
contained PPGf recognition motifs and were included in the
pull-down experiments of nonlabeled cell lysates. 13C-arginine/
13C-lysine labeled lysates were used for pull-downs in the
absence of the inhibitors. Tryptic digest of SDS-PAGE-sepa-
rated proteins was followed by nano-LC mass spectrometric
analysis, allowing the quantification of changes in protein
abundance. Proteins with a strong enrichment of 13C-labeled
peptides relative to unlabeled peptides are indicative of specific
PRS-dependent binding. A full list of the proteins found in these
comparative pull-down experiments and their corresponding
13C/12C peptide ratios are given in Table S1.
For Smy2-GYF, there were three main functional groups
specifically bound by the GYF domain: P body components,
splicing factors, and members of the Hsp70 family. The largest
proportion of these were components of yeast P bodies, which
are cytoplasmic foci important for the translational suppression
and decay of mRNA. P body proteins identified in our pull-
down include typical P body markers such as the Xrn1-exonu-
clease and the Ccr4-NOT complex, as well as two Lsm proteins
(Figure 4). We also pulled down Eap1, an inhibitor of cap-depen-
dent translation (Cosentino et al., 2000), which has been shown
in previous pull-down experiments to interact with Smy2-GYF
(Kofler et al., 2005b).
A set of spliceosomal proteins were the second most abun-
dant group of proteins pulled down by the GYF domain of
Smy2. Apart from BBP, these included Mud2 (a direct binding
partner of BBP) and the two U5 snRNP proteins Prp8 and Brr2.
Prp8 contains two consensus sites for Smy2-GYF, and because
Prp8 directly interacts with Brr2, the latter is probably indirectly
recruited by Smy2-GYF. Surprisingly, we also found strong
enrichment of the Hsp70 chaperones (Table S1A), but there
was only a weak interaction between Smy2-GYF and the
C-terminal part of Hsp71 that contains a motif resembling the
GYF core motif (data not shown). The significance of Hsp70
chaperone enrichment is not clear; however, it is not the first
time Smy2 has been reported to interact with the Hsp70 family
(Zhao et al., 2005).Structure 18, 94Certain homologs of the Smy2 interaction partners were found
in the whole cell lysate pull-down of GIGYF2, including Prp8,
Lsm4, and the human Mud2 homologs U2AF65 and U2AF35
(Table S1A). However, because there is a large number of GYF
domain consensus sites in spliceosomal proteins and hence
a large number of directly and indirectly bound proteins, we
repeated the pull-down experiment with a cytoplasmic fraction
of HeLa cell lysates. GIGYF2 is detected in the cytoplasm of4–954, August 11, 2010 ª2010 Elsevier Ltd All rights reserved 947
Figure 5. Fluorescence Microscopy of
GIGYF2
Live cell images of a HeLa cells cotransfected
with EYFP-Golgi and GIGYF2-ECFP (A–C) and
of ECFP-ER cotransfected with GIGYF2-EYFP
(D–E). In the middle panels, cells were either fixed
and costained with antibodies specific for GIGYF2
and Sec31A (G–J) or were cotransfected with
GFP-Atrophin-1 and CFP-GIGYF2 (K–N). Lower
panels (O–R) show costaining for GIGYF2 and
TIA-1 after arsenite treatment and fixation of cells.
Structure
Structure and Function of Smy2-Type GYF Domainshuman cells under standard conditions (as shown later), lending
support for the search of cytoplasmic binding partners thatmight
be underrepresented in the whole cell lysate pull-down. Impor-
tantly, although components of the COPII coat were only moder-
ately enriched from thewhole cell lysate, they represent themost948 Structure 18, 944–954, August 11, 2010 ª2010 Elsevier Ltd All rights reservedpredominant binding partners in the cyto-
plasm (Table S1A). All four of the core
COPII coat components (Sec31, Sec13,
Sec24, and Sec23) were highly enriched
in our pull-downs, and both Sec24 and
31 contain Smy2-GYF consensus motifs.
Interestingly, several of the interaction
partners of GIGYF2 GYF domain are
proteins that are known components of
stress granules and P bodies (Anderson
and Kedersha, 2008) (Figure 4). These
cytoplasmic granules share a common
set of proteins, whereas others seem to
be exclusively associated with either of
the two. Because typical P body markers
such as the Ccr4-NOT complex or Dcp2,
were absent from the GIGYF2 pull-down
yet typical stress granule proteins, such
as SMN, Caprin-1, and PABP-1, were
identified, we hypothesized that GIGYF2
might be found in the latter struc-
tures. Fluorescencemicroscopy was per-
formed to establish the intracellular
location of GIGYF2.
GIGYF2 Is Associated with the ER
and Golgi and Is Inducibly
Recruited to Stress Granules
Given that the COPII proteins—the
predominant cytoplasmic binding part-
ners for GIGYF2—are associated with
the ER and Golgi, we investigated the
localization of GIGYF2 with both ER and
Golgi markers in HeLa cells. Live cell
images of CFP-tagged GIGYF2 (red)
and YFP-tagged markers for either Golgi
or ER (green) confirmed that GIGYF2 is
associated with these structures (Figures
5A–5F). The specific colocalization of
endogenous GIGYF2 with the COPII
component Sec31A was also tested.Figures 5G–5J show that the two proteins largely overlap in their
cellular distribution and are mainly found in punctuated patterns
typical for ER, Golgi, and vesicular structures. In addition, a few
larger colocalized foci were identified, which were sometimes
situated in the perinuclear region of the cell. Another interesting
Figure 6. Topological Comparison of the Ligand-Binding Site in
Smy2 and CD2BP2
Ligand residues are shown as yellow sticks bound to Smy2-GYF
(A) (sequence: APPPGL) and as blue sticks when bound to CD2BP2-GYF
(B) (sequence: PPPPGH) (PDB accession code: 1L2Z). The tryptophan lid in
CD2BP2 and the critical D22 in Smy2 are labeled in red. An additional cavity,
indicated by a dashed green line, is evident in Smy2, which accommodates the
ligand’s hydrophobic f residue.
Structure
Structure and Function of Smy2-Type GYF Domainsbinding partner identified in our pull-down experiments is Atro-
phin-1 (Nagafuchi et al., 1994) (Table S1), a protein containing
a highly polymorphic polyglutamine region that leads to denta-
torubral pallidoluysian atrophy when expanded to 49–75 repeats
instead of the normal 7–23 repeats. Atrophin-1 contains four
optimal GIGYF2 recognition motifs, and when it was examined
for colocalization of GFP- and YFP-fused versions of the respec-
tive proteins, we found a strong correlation in their compartmen-
tation in HeLa cells (Figures 5K–5N). Both proteins favorably
localize to cytoplasmic foci that, at least in part, should be attrib-
utable to the ER and Golgi compartments that were found to
costain with GIGYF2 in Figures 5A–5F.
Because the SILAC results suggested GIGYF2 is associated
with stress granules, the localization of GIGYF2 was tested in
HeLa cells treated with arsenite (a comparison with untreated
HeLa cells is shown in Figure S2). TIA-1 was used as a marker
because it is a well-described component of stress granules.
Figures 5O–5R clearly show that GIGYF2 is contained within
the same granules to which TIA-1 is recruited, indicating that
stress conditions drive GIGYF2 into these structures. These
microscopy experiments therefore suggest that the Parkinson-
associated protein GIGYF2 is involved in vesicular transport
between ER and Golgi, but is driven mainly into stress granules
upon arsenite treatment.
DISCUSSION
The Structure of GYF Domains
From S. cerevisiae to Homo sapiens, GYF domains are present
within a small group of proteins that have retained their PRS-
binding specificities. Two major families of GYF domains were
suggested on the basis of sequence comparison and recognition
profiles. Here, themolecular detail of target specificity is revealed
through a structure of the GYF domain of the yeast Smy2 protein
in complex with a PPGf-containing peptide fragment. The struc-
ture shows that aspartic acid 22 is the critical class-determining
factor. A triage of hydrogen bonds pulls the side-chain of D22
away from a hydrophobic cavity, thus readying the cleft to
accommodate ahydrophobic amino acid following thePPGmotif
in the ligand (Figure 3, inset, and Figure 6). Unlike Smy2-typeGYF
domains, CD2BP2-type GYF domains contain a ‘‘tryptophan lid’’
(Figure 6) that shields the critical hydrophobic cavity but allows
the p-stacking of bulky ligand residues, such as tryptophan or
arginine. In this way, the two domain subfamilies have evolved
differing specificities for their proline-rich target sequences.
Distinguishing the Two GYF Domain Subfamilies
The pocket formed by residues Y20, F45, and L49 is the distin-
guishing feature of Smy2-type GYF domains, because it is
occluded from the binding epitope in CD2BP2-type GYF
domains (Figure 6). The conserved and bulky W22 points inward
toward the ligand-binding site in the CD2BP2 GYF domain and,
in doing so, obscures the extended binding pocket. In contrast,
D22 in Smy2-GYF is oriented away from the hydrophobic patch,
exposing L49 and presenting the extended hydrophobic inter-
face to the ligand. It is this critical difference that determines
the binding specificities of the two domain subfamilies. The
extended hydrophobic cleft selects for a moderately sized
hydrophobic amino acid following the PPGmotif, with the pocketStructure 18, 94too small to comfortably accommodate tryptophan. In this way,
PPGW is excluded as a high-affinity interaction motif for Smy2-
type GYF domains. Conversely, CD2BP2-GYF selects for
PPGW in phage display experiments, with the ligand tryptophan
suggested to form a stacking interaction with the domain W22
(Freund et al., 2002). For the CD2BP2-GYF domain, a second
type of preferred binding motif exists that displays the signature
PPGX(R/K). For this type of PRS, at least one positively charged
residue has to be contained in the motif, whereas charge depen-
dence is not observed for Smy2-type GYF domains.
To maintain the side-chain orientation of D22 in Smy2-GYF
such that it points away from the hydrophobic cleft, its carboxyl
groups form three hydrogen bonds: two with the main chain
amide groups of residues Q24 and Q26 and one with the NE2
group of H28 (Figure 3, inset). The importance of these hydrogen
bonds is evidenced in their conservation between all Smy2-type
GYF domains. There is total maintenance of a hydrogen bond
donor at position 28, whose side-chain amide groups act as
a hydrogen bond donor to D22. In addition, another feature of
the Smy2-GYF subfamily is a shorter loop between b strands
1 and 2 (T23-G25). This shortened loop allows the backbone
amide of Q24 to be in close enough proximity to form a hydrogen
bond with the D22 side-chain. All key residues defining the
specificity of the PRS binding site are conserved in human
GIGYF2 (Figure 1), and GIGYF2 has been shown to bind
selectively to the PPGf motif characteristic of Smy2-type GYF
domains (Kofler et al., 2005b). The Smy2 structure presented
here may thus be considered an excellent model for the human
GIGYF2 GYF domain.4–954, August 11, 2010 ª2010 Elsevier Ltd All rights reserved 949
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Structure and Function of Smy2-Type GYF DomainsDespite the distinct differences in their binding pockets, cross-
binding between Smy2-type and CD2BP2-type GYF domains
might still occur for certain sequences in the respective pro-
teomes. Previous studies from our group showed that human
CD2BP2 and GIGYF2 are able to recognize certain sequences
that obey the recognition rules for both domains (Kofler et al.,
2005a, 2005b). For example, the SmB/B’ core splicing protein
contains a C-terminal PPPGIR motif that can bind to both type
of GYF domains, as highlighted in spot 36 of Figure S3 (sequence
given in Table S2), which shows the peptide SPOT membranes
from previous results in a color coded superposition. Conse-
quently, SmB/B’ interacted with both GYF proteins in a yeast-
two-hybrid analysis; however, because the splicing machinery
is located in the cell nucleus, it is most likely that CD2BP2 is
the prominent interaction partner of SmB/B’ under most physio-
logical conditions.
Smy2 and GIGYF2 in mRNA Surveillance and P Bodies
In agreement with previous studies from our group on PRS
recognition domains, we identified distinct molecular complexes
in our SILAC experiments that were bound to GYF domains in
a PRS-dependent manner (Kofler et al., 2009; Schlundt et al.,
2009). Only some of the proteins would contain recognition
motifs, whereas the other components would be most probably
recruited via their tight association with a PRS-containing direct
binding partner. It is likely that Smy2 is recruited to the so-called
processing bodies via an interaction with Xrn1 and components
of the Ccr4-NOT complex, because these proteins contain
PPGf consensusmotifs. Although we cannot exclude additional
interaction sites to be present in Smy2-GYF, the large enrich-
ment factors for many non-PPGf-containing proteins point
toward an indirect recruitment of the other P body proteins
that were identified in our SILAC/MS pull-down experiments. P
bodies are cytoplasmic foci containing translationally repressed
mRNAs and their associated proteins (Bruno and Wilkinson,
2006). Inside this distinct and dynamic cytoplasmic compart-
ment, mRNA can be degraded by resident P body proteins or
sequestered until it is released back into the active translation
cycle (Bruno and Wilkinson, 2006; Eulalio et al., 2007; Kedersha
and Anderson, 2007). Many of the core P body proteins were
identified in our pull-downs, including seven of the nine Ccr4-
NOT complex components, two Lsm proteins, and Xrn1. These
findings strongly suggest a role for Smy2 in P bodies and
mRNA surveillance. In support of this, Smy2 and its paralog
Syh1 were shown to colocalize with Dcp2 in P bodies (Georgiev
et al., 2007). Although the translational repressor Eap1 is not
associated with P bodies, its identification in our pull-down
experiments and previous studies (Deloche et al., 2004) draws
a further link between Smy2 and translational control. The phys-
iological importance of the Smy2-Eap1 interaction was vigor-
ously shown by a recent study that linked these two proteins
to translation inhibition of a specific mRNA (Sezen et al., 2009).
Their work showed that a genetic defect of the Mps2 protein
that anchors the newly formed spindle pole body to the nuclear
envelope can be rescued by high dosages of Smy2. As a conse-
quence, the mRNA coding for the nuclear pore complex protein
POM34 is translationally inhibited by recruitment of Eap1 to the
POM34 mRNA-binding protein Scp160. The C-terminal PPGL
motif of Eap1 and an intact GYF motif in Smy2 were shown to950 Structure 18, 944–954, August 11, 2010 ª2010 Elsevier Ltd All ribe essential for mediating this effect. Taken together, these
results suggest that Smy2 possesses mRNA surveillance func-
tions, such as mRNA degradation or translation inhibition, which
are mediated by its recruitment of PPGf-containing proteins.
However, the question why an additional adaptor protein like
Smy2 is needed to bridge mRNA-associated proteins with
these mRNA regulatory proteins remains unanswered. Investi-
gating a possible RNA-binding function of Smy2 itself or
determining whether regulatory posttranslational modifications
drive assembly of the Smy2 protein complex are certainly
important for a more thorough understanding of Smy2-mediated
processes.
A number of splicing proteins were identified in our pull-downs
as potential interaction partners of Smy2. Although Smy2 is
unlikely to be involved in splicing, it is possible that the identified
spliceosomal proteins aremoonlighting in the transport of mRNP
particles under certain cellular conditions. One such example is
the Lsm proteins, which form subcomplexes that are either
involved in spliceosome assembly in the nucleus or in mRNA
degradation in the cytoplasm (Beggs, 2005). Smy2 and BBP
are supposed to localize to the cytoplasm and nucleus, respec-
tively (Huh et al., 2003), but the compartmentalization of BBP is
yet to be challenged under conditions of cell division or stress.
There were many mRNA-processing proteins identified in both
pull-downs with the GIGYF2-GYF domain. Most of these were
nuclear proteins involved in splicing. Notably absent, however,
were the Ccr4-NOT proteins which were the predominant cyto-
plasmic binding partners for Smy2. Although yeast P body
proteins contain several PPGf motifs, they are only present
as single motifs in Not1 and Not4 in the corresponding human
proteins. The reduced occurrence of PPGf motifs might
account for this difference in specificity between Smy2 and
GIGYF2, or it might be due to the variable C termini in the two
domains. Interestingly, we did not find Grb10 as a binding
partner for the GYF domain of GIGYF2, as was suggested else-
where (Giovannone et al., 2003). Although it is still possible that
Grb10 was absent from our cell lysates, it is noteworthy that
mouse Grb10 contains a PPGF motif, whereas no Smy2-type
recognition motif is present in human Grb10. We suggest that
a direct GIGYF2-Grb2 interaction in mouse is replaced by other
interfaces or indirect binding in the case of the human proteins.
GIGYF2 was found in stress granules when cells were treated
with arsenite. Stress granules are cytoplasmicmRNA-containing
foci that are assembled during cell stress. These are closely
related to but distinct from P bodies. It is yet to be seen whether
this localization is mediated by its GYF domain as for Smy2, or
whether the Q/N-rich region in full-length GIGYF2 might be
responsible—a feature known to be associated with P and stress
body formation (Gilks et al., 2004; Reijns et al., 2008).
Smy2 and GIGYF2 in Vesicular Transport
The current results implicating Smy2 in an mRNA surveillance
role are contrasted by recent reports suggesting secretion-
related functions for Smy2 and its paralog Syh1 (Georgiev
et al., 2008; Higashio et al., 2008). Smy2 exhibits genetic interac-
tions with proteins from the secretory pathway, namely Sec22,
Bet1, Sec16, Sec24, Sec31, and Sec34 (Higashio et al., 2008).
In fact, a number of Smy2 binding partners identified in our
SILAC experiments also have both physical and geneticghts reserved
Structure
Structure and Function of Smy2-Type GYF Domainsinteractions with the secretory pathway. These include Not1
(Gavin et al., 2006), Lsm2 (Fromont-Racine et al., 2000), and
Eap1 (Deloche et al., 2004).
Taken together, these results suggest the dual involvement of
Smy2 in both mRNA processing and secretion, and add to an
increasing body of evidence suggesting that splicing, mRNA
surveillance, and translation are linked with the secretory
pathway in S. cerevisiae (Awasthi et al., 2001; Chang et al.,
2008; Davydenko et al., 2004; Decourty et al., 2008; Frigieri
et al., 2007; Jackson and Kepes, 1994; Lang et al., 2001;
Li et al., 2000; Mizuta and Warner, 1994; Nelson and Lemmon,
1993; Trautwein et al., 2004).
Despite apparent connections with the secretory pathway,
in particular with COPII vesicle components (Higashio et al.,
2008), secretory proteins were absent in the Smy2 pull-down.
Interestingly though, the COPII proteins represented a highly
enriched fraction of cytoplasmic proteins interacting with the
GYF domain of human GIGYF2, and we could show colocaliza-
tion of full-length GIGYF2 with Sec31A in HeLa cells. YFP-
GIGYF2 also colocalized with ER and Golgi markers in live cells
(Figure 5). These findings are consistent with the existence of
GYF domain consensus motifs in human COPII components,
which are absent in their S. cerevisiae counterparts. This study
provides the first evidence that human GIGYF2 might be
involved in the secretory pathway.
The current study draws some striking parallels between
S. cerevisiae Smy2 and human GIGYF2, which contain little
sequence identity outside of their Smy2-GYF domains. Both
recognize PPGf motifs in a structurally conserved manner,
interact with a common set of mRNA processing proteins, and
localize to the Golgi/ER and cytoplasmic mRNA-containing
granules. Yet despite these parallels, some interesting differ-
ences are also apparent. Smy2 exhibits a genetic interaction
with but does not bind to native COPII proteins, yet these were
the predominant cytoplasmic binding partners for GIGYF2.
Conversely, Smy2 interacts with the Ccr4-NOT P body proteins,
which were not identified in the GIGYF2 pull-down. These results
suggest that although an evolutionary drift of PRS occurrence
may have changed the direct interactome of the Smy2-GYF
domain in yeast and humans, both proteins exhibit an intriguing
dual involvement in mRNA processing and secretion.
GIGYF2 and Its Potential Role in Neuronal Dysfunction
Given the burst of articles alluding to the potential role of the
GIGYF2 gene in the development of Parkinson’s disease (Tan
and Schapira, 2010), we believe that a molecular understanding
of GIGYF2 is mandatory. In this regard, our structure provides
a good starting point for the rationalization of mutations
and the design of peptide-derived inhibitors. For example, the
L601F mutation recently described in a patient with Parkinson’s
disease from China (reviewed in Wang et al., 2010) could well
interfere with the tight packing of the hydrophobic core, poten-
tially leading to a destabilization of the domain and consequently
to altered binding properties.
As outlined above, our data indicate a role for GIGYF2 in trans-
port processes. Directed and regulated navigation of mRNA and
proteins are a prerequisite for the production of proteins at
specific subcellular locations, which is of particular importance
for axonal transport. Many of the proteins that were found inStructure 18, 94our pull-down experiments are known to bind RNA; however,
it will be of utmost importance to specifically identify GIGYF2-
associated RNAs. Is it possible that GIGYF2, in analogy to the
Smy2-regulated sequestration of POM34 mRNA in yeast (Sezen
et al., 2009), is an important factor for the compartmentation of
stress-responsive mRNA? In addition, the role of the glutamine
repeats of the protein should be investigated in regard to their
potential to drive stress granule localization. Similarly, it has to
be proven that PRS recognition by GYF domains steers the
protein into certain assemblies that are of real functional impor-
tance. Interestingly, two proteins associated with neuronal
dysfunction, Atrophin-1 and PQBP-1, also interact with GIGYF2
(Table S1). Expansion of glutamine repeats in Atrophin-1 lead to
dentatorubral pallidoluysian atrophy (Nagafuchi et al., 1994),
whereas PQBP-1 is causative for certain forms of mental retar-
dation (Kalscheuer et al., 2003). Atrophin-1 not only contains
four optimal PRS motifs for the GYF domain of GIGYF2 but
also several potential binding sites for the WW domain of
PQBP-1. GIGYF2 and PQBP-1 might additionally interact via
the polyglutamine stretches of GIGYF2 and the polar amino
acid repeats of PQBP-1. It will be interesting to delineate the
possible interplay among these three proteins in the context of
neuronal models of stress and disease.
EXPERIMENTAL PROCEDURES
Protein Constructs and Expression
Full-length human GIGYF2 was amplified from IMAGE clone
DKFZp686HO3114Q2 by PCR using Vent polymerase (New England Biolabs)
and was cloned into the HindIII and SalI restriction sites of the vector pEYFP-
C1 and pECFP-C1 (Clontech). pEYFP-Golgi and pECFP-ER (Clontech) were
kindly provided by Ralf Schuelein, and GFP-Atrophin-1 (pEGFP-DRPLA-Q71)
was a kind gift from Zoya Ignatova. Cloning and expression of the GST-fusion
proteins of Smy2-GYF (Swiss-Prot accession number P32909; residues
193–290) and GIGYF2-GYF (Swiss-Prot accession number O75137; residues
531–596) were essentially performed as described elsewhere (Kofler et al.,
2005b).
Peptide Synthesis
Peptides were synthesized automatically by solid phase methods using stan-
dard Fmoc chemistry in a batch-wise mode (Beyermann et al., 1996). Final
cleavage and deprotection by TFA/H2O (9:1) resulted in crude peptides that
were further purified to >95% by HPLC. The expected mass of peptides was
verified by mass spectrometry.
Preparation of Smy2-GYF for Crystallization
For crystallization of unligated Smy2-GYF, recombinant protein was
expressed and purified from E. coli as described elsewhere (Kofler et al.
2005b). Before crystallization, the sample was dialyzed into buffer containing
20 mM HEPES and 150 mM NaCl (pH 7.3) and was concentrated to 13
mg/mL. To produce selenomethionine-labeled Smy2-GYF, a pET28 plasmid
containing the Smy2-GYF construct was transformed into methionine-auxo-
tropic E. coli B834 (DE3) cells. Cells were grown on New Minimal Medium,
as described elsewhere (Budisa et al. 1995), and were purified and dialyzed
as for the unlabeled protein. For ligand binding, selenomethionine-labeled
Smy2-GYF was incubated overnight at 4C with Msl5-S ligand
(SSIAPPPGLSG) using a 1:10 ratio of protein to ligand. The mixture was
concentrated to 26 mg/mL before crystallization
Crystallization and Data Collection
All crystals were grown at 20C using the sitting drop vapor diffusion method
and began to appear after seven days. Protein solution (200 nL) was mixed
with an equal volume of reservoir solution. The reservoir buffers contained
18% polyacrylic acid, 0.15 M MgCl2, and 0.1 M Na-HEPES (pH 7.5) for the4–954, August 11, 2010 ª2010 Elsevier Ltd All rights reserved 951
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ligand complex.
A native 1.8 A˚ data set (0.91841 A˚) for the domain alone was collected at
100 K at the Protein Structure Factory beamline BL14.2 of the Free University
of Berlin at BESSY (Berlin, Germany) on a 225-mm MarCCD detector.
A MAD data set to 2.5 A˚ consisting of peak (0.978522 A˚) and inflection point
(0.97875 A˚) wavelengths was collected on the Se-Met substituted Smy2-
GYF at 100 K on beamline BM14 at the ESRF.
Cryo-protection for both crystals was mother liquor plus 20% (v/v) glycerol.
Unligated Smy2-GYF crystallized with one molecule in the asymmetric unit in
space group P6522 with unit cell dimensions a = b = 68.4 A˚ and c = 111.3 A˚,
while the complex crystallized in spacegroup P42212 and unit cell dimensions
a = b = 101.4 A˚ and c = 150.7 A˚. There were five domain-ligand complexes in
the asymmetric unit.
Structure Determination and Refinement
All data were processed using MOSFLM (Leslie, 1992) and were scaled with
SCALA (Evans, 1993). For the domain-ligand complex, the positions of 16 sele-
nium sites and initial phases to 2.5 A˚ were calculated using the SHELXC/D/E
package (Sheldrick, 2008). More than 90% of the backbone could be traced
through multiple runs of ARP/wARP (Perrakis et al., 1999), and the addition
of side-chains and further manual model building were performed in Coot
(Emsley and Cowtan, 2004). The model was refined against the peak data
set using REFMAC5 (Murshudov et al., 1997; CCP4, 1994) including TLS
refinement (Winn et al., 2001). Tight NCS restraints were applied during refine-
ment and were relaxed yet maintained in the final stages. The final model
includes three water molecules. Despite the moderate resolution, clear alter-
native conformations for M35 in chains A and C could be visualized. Refine-
ment was completed with Rwork = 0.225 and Rfree = 0.250. The average protein
factor of the final model is 61.5 A˚2. The structure of Smy2-GYF alone was
solved bymolecular replacement with Phaser (McCoy et al., 2007), using chain
A of the Smy2-GYF-ligand structure as a search model. Molecular replace-
ment produced a single unique solution, and refinement was performed in
REFMAC5 (Murshudov et al., 1997) including TLS refinement (Winn et al.,
2001). Refinement converged with residuals Rwork = 0.208 and Rfree = 0.224.
The final models were subjected to extensive validation using SFCHECK
(Vaguine et al., 1999), WHAT IF (Vriend, 1990), and MolProbity (Davis et al.,
2007). Crystallographic data and refinement statistics are given in Table 1.
Cell Culture
HeLa S3 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal calf serum (Biochrom). Cells were incubated at
37C under 5% CO2/95% air.
Stable Isotope Labeling and Preparation of Cell Extracts
SILAC was performed similar to previously published protocols (Ong et al.,
2002) and is described in detail in Supplemental Experimental Procedures.
Commercially available SILAC and DMEM media were obtained from Cam-
bridge Isotope Laboratories (Andover, MA) and Invitrogen, respectively.
Pull-Down Experiments, MS Sample Preparation, and Analysis
Pull-down experiments were essentially performed as described elsewhere
(Kofler et al., 2009) and relied on the differential inhibition of the PRS-binding
site by Msl-5 peptide. For MS analysis, Coomassie-stained gel bands were
cut into slices (resulting in 40–50 slices per pull-down), and proteins were
in-gel-digested with trypsin, as described elsewhere (Klemm et al., 2006).
Details of the protocol and the identification and quantification of proteins
from SILAC pull-downs are further described in Supplemental Experimental
Procedures.
Transfection and Fluorescence Microscopy
HeLa S3 cells (1 3 104) were grown on poly-ornithine-coated coverslips
(Menzel-Glaeser). After one day, cells were either transfected with fuGENE 6
(ROCHE) and 0.5 mg DNA/well, according to the manufacturer’s protocol for
live cell imaging, or were fixed for endogenous protein staining. Twenty-four
hours after transfection, HeLa cells were examined by confocal laser scanning
microscopy, as described in Supplemental Experimental Procedures.952 Structure 18, 944–954, August 11, 2010 ª2010 Elsevier Ltd All riGeneration of Antibodies
The GIGYF2-GYF domain was expressed in E. coli BL21 (DE3) and was
purified as described elsewhere (Kofler et al., 2005b). The 8 kDa protein was
conjugated with the carrier protein Limulus polyphemus hemocyanin (LPH)
and was used for immunization of rabbits (Biogenes GmBH, Berlin, Germany).
Monoclonal antibodies against TIA-1 and Sec31A were purchased from Santa
Cruz Biotechnology.ACCESSION NUMBERS
Protein coordinates and structure factor amplitudes have been deposited in
the Protein Data Bank under accession codes 3FMAV (complex) and 3K3V
(domain alone).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, two tables, and Supple-
mental Experimental Procedures and may be found with this article online at
doi:10.1016/j.str.2010.04.020.
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